Exome Asset Management’s 10x Genomics TXG Stock Holding History

Exome Asset Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.93M	Sell	102,629 -51,565	-33%	-$1.35M	2.43%	13
2026 Q1	$3.27M	Sell	154,194 -9,464	-6%	-$189K	1.69%	23
2025 Q4	$2.67M	Hold	163,658	–	–	1.28%	33
2025 Q3	$1.91M	Hold	163,658	–	–	1.16%	35
2025 Q2	$1.9M	Buy	+163,658	New	+$1.49M	1.41%	30

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Exome Asset Management's TXG Position: Q2 2026 in Review

Exome Asset Management reduced its 10x Genomics (TXG) stake by 33% in Q2 2026, selling an estimated $1.35M and leaving 102,629 shares worth $3.93M. The position accounts for 2.43% of the portfolio, ranked #13.

Exome Asset Management first reported a position in TXG in Q2 2025 and has held it in 5 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Exome Asset Management held 102,629 shares of 10x Genomics worth $3.93M as of Q2 2026.
Exome Asset Management sold 51,565 10x Genomics shares in Q2 2026, an estimated $1.35M.
10x Genomics made up 2.43% of Exome Asset Management's portfolio in Q2 2026, its #13 holding.
Exome Asset Management first reported a position in 10x Genomics in Q2 2025 and has held it in 5 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.